Helus Pharma (Cybin Inc.) to Participate in H.C. Wainwright 7th Annual Neuro Perspectives Conference

Cybin Inc. (operating as Helus Pharma) announced that its Chief Medical Officer, Amir Inamdar, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The event is scheduled for June 15-16, 2026, with the presentation available on demand starting June 15. Helus Pharma is a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health conditions. The filing highlights the company's lead programs: HLP003, a proprietary NSA currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD), which has received FDA Breakthrough Therapy Designation; and HLP004, a Phase 2 candidate for generalized anxiety disorder (GAD). The company continues to advance its research portfolio of investigational NSAs aimed at promoting neuroplasticity. No new clinical data or material financial updates were disclosed in this announcement.